<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816591</url>
  </required_header>
  <id_info>
    <org_study_id>CNV_2020_01</org_study_id>
    <nct_id>NCT04816591</nct_id>
  </id_info>
  <brief_title>Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA</brief_title>
  <acronym>MEMBRANE</acronym>
  <official_title>Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerenovus, Part of DePuy Synthes Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerenovus, Part of DePuy Synthes Products, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, open-label, randomized controlled study in which&#xD;
      subjects can receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization&#xD;
      for the treatment of chronic subdural hematomas (cSDH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, open-label, randomized controlled study in which up to&#xD;
      376 subjects will be randomized to receive standard of care (SOC) alone or SOC and TRUFILL&#xD;
      n-BCA MMA embolization for the treatment of cSDH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>180 days post procedure</time_frame>
    <description>Hematoma recurrence/progression or requiring re-intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>180 days post procedure</time_frame>
    <description>Reduction of hematoma volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Change in mRS</measure>
    <time_frame>180 days post procedure</time_frame>
    <description>Change in mRS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health Economics</measure>
    <time_frame>365 days post procedure</time_frame>
    <description>Hospital days</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Experimental: Interventional Cohort: Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of Care Surgery + Embolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Interventional Cohort: Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care Surgery Only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Observational Cohort: Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of Care Medical Management + Embolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Observational Cohort: Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical Management Only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Experimental: Interventional Cohort: Treatment Arm</intervention_name>
    <description>Standard of Care Surgery + Embolization</description>
    <arm_group_label>Experimental: Interventional Cohort: Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator: Interventional Cohort: Control Arm</intervention_name>
    <description>Standard of Care Surgery Only (Control)</description>
    <arm_group_label>Active Comparator: Interventional Cohort: Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Experimental: Observational Cohort: Treatment Arm</intervention_name>
    <description>Standard of Care Medical Management + Embolization</description>
    <arm_group_label>Experimental: Observational Cohort: Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator: Observational Cohort: Control Arm</intervention_name>
    <description>Standard of Care Medical Management Only (Control)</description>
    <arm_group_label>Active Comparator: Observational Cohort: Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-randomization mRS &lt;/= 3&#xD;
&#xD;
          -  Confirmed diagnosis of chronic subdural hematoma&#xD;
&#xD;
          -  Completed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute subdural hematoma&#xD;
&#xD;
          -  Prior treatment of target subdural hematoma&#xD;
&#xD;
          -  Markwalder assessment &gt;/= 3&#xD;
&#xD;
          -  Glasgow Coma Scale &lt; 9&#xD;
&#xD;
          -  Presumed microbial superinfection&#xD;
&#xD;
          -  CT or MRI evidence of intracranial tumor or mass lesion&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Women who are pregnant, lactating, or who are of childbearing age and plan on becoming&#xD;
             pregnant during the study&#xD;
&#xD;
          -  Current involvement in another clinical trial that may confound study endpoints&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Kellner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MOUNT SINAI HOSPITAL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ansaar Rai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lillian Ma</last_name>
    <phone>9494668021</phone>
    <email>lma46@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Subdural Hematoma, MMA Embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu.</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

